全文获取类型
收费全文 | 2759篇 |
免费 | 207篇 |
国内免费 | 45篇 |
专业分类
耳鼻咽喉 | 40篇 |
儿科学 | 84篇 |
妇产科学 | 62篇 |
基础医学 | 353篇 |
口腔科学 | 38篇 |
临床医学 | 300篇 |
内科学 | 632篇 |
皮肤病学 | 21篇 |
神经病学 | 160篇 |
特种医学 | 377篇 |
外国民族医学 | 26篇 |
外科学 | 323篇 |
综合类 | 36篇 |
一般理论 | 1篇 |
预防医学 | 153篇 |
眼科学 | 46篇 |
药学 | 157篇 |
中国医学 | 2篇 |
肿瘤学 | 200篇 |
出版年
2022年 | 19篇 |
2021年 | 39篇 |
2020年 | 24篇 |
2019年 | 53篇 |
2018年 | 71篇 |
2017年 | 48篇 |
2016年 | 47篇 |
2015年 | 58篇 |
2014年 | 81篇 |
2013年 | 107篇 |
2012年 | 131篇 |
2011年 | 128篇 |
2010年 | 99篇 |
2009年 | 89篇 |
2008年 | 115篇 |
2007年 | 143篇 |
2006年 | 108篇 |
2005年 | 107篇 |
2004年 | 104篇 |
2003年 | 86篇 |
2002年 | 80篇 |
2001年 | 73篇 |
2000年 | 75篇 |
1999年 | 73篇 |
1998年 | 57篇 |
1997年 | 50篇 |
1996年 | 53篇 |
1995年 | 49篇 |
1994年 | 61篇 |
1993年 | 45篇 |
1992年 | 58篇 |
1991年 | 46篇 |
1990年 | 41篇 |
1989年 | 80篇 |
1988年 | 54篇 |
1987年 | 73篇 |
1986年 | 66篇 |
1985年 | 42篇 |
1984年 | 34篇 |
1983年 | 26篇 |
1982年 | 17篇 |
1981年 | 16篇 |
1980年 | 14篇 |
1979年 | 15篇 |
1975年 | 16篇 |
1974年 | 18篇 |
1973年 | 12篇 |
1972年 | 14篇 |
1971年 | 12篇 |
1969年 | 13篇 |
排序方式: 共有3011条查询结果,搜索用时 15 毫秒
61.
62.
Zielinsky A; Hirsh J; Straumanis G; Carter CJ; Gent M; Sackett DL; Hull R; Kelton JG; Powers P; Turpie AG 《Blood》1982,59(2):346-350
We have evaluated the fibrinogen/fibrin fragment E antigen assay as a diagnostic test in patients with clinically suspected venous thrombosis by comparing the results of this assay with venography in 272 patients. The result of the fragment E antigen assay was elevated in 79 of 80 patients with positive venograms for recent venous thrombosis (sensitivity 99%) and within the normal range in 161 of 192 patients with normal venograms (specificity 84%). The fragment E assay was also evaluated in 130 medical and surgical controls without evidence of venous thrombosis by leg scanning and the test was found to be relatively nonspecific. However, in the patient group under study, a correct clinical diagnosis of no thrombosis, based on a normal fragment E result, was made in 161 of 162 cases (negative predictive value of 99%). Therefore, a normal test result effectively excludes a diagnosis of venous thrombosis in clinically symptomatic patients. The assay, as currently performed, is technically demanding and takes 24 hr to complete. Therefore, it will have to be simplified before it can be applied to clinical practice. 相似文献
63.
Jacqueline AM Smith DL Patil OT Daniels Y-S Ding J-D Gallezot S Henry KHS Kim S Kshirsagar WJ Martin GP Obedencio E Stangeland PR Tsuruda W Williams RE Carson ST Patil 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2015,18(2)
Background:
Monoamine reuptake inhibitors exhibit unique clinical profiles that reflect distinct engagement of the central nervous system (CNS) transporters.Methods:
We used a translational strategy, including rodent pharmacokinetic/pharmacodynamic modeling and positron emission tomography (PET) imaging in humans, to establish the transporter profile of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor.Results:
TD-9855 was a potent inhibitor of norepinephrine (NE) and serotonin 5-HT uptake in vitro with an inhibitory selectivity of 4- to 10-fold for NE at human and rat transporters. TD-9855 engaged norepinephrine transporters (NET) and serotonin transporters (SERT) in rat spinal cord, with a plasma EC50 of 11.7ng/mL and 50.8ng/mL, respectively, consistent with modest selectivity for NET in vivo.Accounting for species differences in protein binding, the projected human NET and SERT plasma EC50 values were 5.5ng/mL and 23.9ng/mL, respectively. A single-dose, open-label PET study (4–20mg TD-9855, oral) was conducted in eight healthy males using the radiotracers [11C]-3-amino-4- [2-[(di(methyl)amino)methyl]phenyl]sulfanylbenzonitrile for SERT and [11C]-(S,S)-methylreboxetine for NET. The long pharmacokinetic half-life (30–40h) of TD-9855 allowed for sequential assessment of SERT and NET occupancy in the same subject. The plasma EC50 for NET was estimated to be 1.21ng/mL, and at doses of greater than 4mg the projected steady-state NET occupancy is high (>75%). After a single oral dose of 20mg, SERT occupancy was 25 (±8)% at a plasma level of 6.35ng/mL.Conclusions:
These data establish the CNS penetration and transporter profile of TD-9855 and inform the selection of potential doses for future clinical evaluation. 相似文献64.
Dziennis S; Van Etten RA; Pahl HL; Morris DL; Rothstein TL; Blosch CM; Perlmutter RM; Tenen DG 《Blood》1995,85(2):319-329
CD11b is the alpha chain of the Mac-1 integrin and is preferentially expressed in myeloid cells (neutrophils, monocytes, and macrophages). We have previously shown that the CD11b promoter directs cell-type- specific expression in myeloid lines using transient transfection assays. To confirm that these promoter sequences contain the proper regulatory elements for correct myeloid expression of CD11b in vivo, we have used the -1.7-kb human CD11b promoter to direct reporter gene expression in transgenic mice. Stable founder lines were generated with two different reporter genes, a Thy 1.1 surface marker and the Escherichia coli lacZ (beta-galactosidase) gene. Analysis of founders generated with each reporter demonstrated that the CD11b promoter was capable of driving high levels of transgene expression in murine macrophages for the lifetime of the animals. Similar to the endogenous gene, transgene expression was preferentially found in mature monocytes, macrophages, and neutrophils and not in myeloid precursors. These experiments indicate that the -1.7 CD11b promoter contains the regulatory elements sufficient for high-level macrophage expression. This promoter should be useful for targeting heterologous gene expression to mature myeloid cells. 相似文献
65.
66.
67.
68.
69.
Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects 总被引:1,自引:0,他引:1
McClean DR Ikram H Mehta S Heywood JT Rousseau MF Niederman AL Sequeira RF Fleck E Singh SN Coutu B Hanrath P Komajda M Bryson CC Qian C Hanyok JJ;Omapatrilat Hemodynamic Study Group 《Journal of the American College of Cardiology》2002,39(12):2034-2041
OBJECTIVES: We investigated the acute and long-term hemodynamic and neurohumoral effects of the vasopeptidase inhibitor omapatrilat in human heart failure. BACKGROUND: Angiotensin-converting enzyme (ACE) inhibition constitutes a major advance in the treatment of chronic heart failure (CHF). Simultaneous inhibition of both neutral endopeptidase and ACE with omapatrilat may represent a new treatment strategy in CHF. METHODS: Three hundred and sixty-nine patients with symptomatic heart failure were randomized to double-blind treatment with omapatrilat (first 190 patients: 2.5 mg, 5 mg or 10 mg; last 179 patients: 2.5 mg, 20 mg or 40 mg once daily) for 12 weeks. RESULTS: Acutely, the 10 mg, 20 mg and 40 mg doses of omapatrilat produced greater reductions in pulmonary capillary wedge pressure (PCWP), systolic blood pressure (SBP) and systemic vascular resistance compared with 2.5 mg. Higher doses were associated with greater increases in vasodilator and natriuretic peptides, in addition to ACE inhibition. After 12 weeks, omapatrilat 20 mg and 40 mg showed greater falls from baseline in PCWP (40 mg: 0 h to 12 h average change -7.3 +/- 0.8 mm Hg) and SBP (40 mg: -11.7 +/- 1.7 mm Hg) than 2.5 mg (both p < 0.01 vs. 2.5 mg). The incidence of adverse experiences and patient withdrawal were similar in all groups. CONCLUSIONS: In CHF, the acute hemodynamic benefit seen with higher doses of omapatrilat was associated with increases in plasma vasodilator and natriuretic peptide levels in addition to ACE inhibition. After 12 weeks, the hemodynamic benefit was maintained. Omapatrilat may be a promising new agent in CHF. 相似文献
70.